Authors

Latest:

Dr Krishnamurthy on Treatment Sequencing Based on Mutation Status in HR+/HER2– Breast Cancer

Jairam Krishnamurthy, MD, FACP, discusses the use of mutation status to inform treatment sequencing in HR-positive, HER2-negative metastatic breast cancer.

Christian Buske, MD,

Latest:

Dr. Buske on the Results of the iNNOVATE Trial in Waldenström Macroglobulinemia

Christian Buske, MD, discusses the results of the iNNOVATE trial in Waldenström macroglobulinemia.

Rohan Jeyarajah, MD

Latest:

Dr. Jeyarajah on Aggressive Treatment while Preserving Quality of Life in CRC

Rohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.

Oleg Bess, MD

Latest:

Data Quality Issues Plague the US Health Care System

Oleg Bess, MD, explains why data quality is essential to improving the United States health care system.

Stacey Stein, MD

Latest:

Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC

Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.

Ashley Sumrall, MD

Latest:

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

Preetesh Jain, MD, PhD

Latest:

Dr. Jain on Ongoing Research Efforts in MCL

Preetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.

Deborah B. Doroshow, MD, PhD

Latest:

Dr Doroshow on RET Inhibitors in RET Fusion+ NSCLC

Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.

Eva M. Ciruelos Gil, MD, PhD

Latest:

Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.

Sikander Ailawadhi, MD

Latest:

Dr Ailawadhi on Early Data for Iopofosine I 131 in Waldenström Macroglobulinemia

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

Nilay Shah, MD

Latest:

Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid Tumors

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Steven Waguespack, MD

Latest:

Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid Carcinoma

Dr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

Stephan L. Chan, MD, The Chinese University of Hong Kong

Latest:

Future Directions for HCC Management

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.

Shumei Kato, MD

Latest:

Dr. Kato on the Characterization of BRAF Mutations in Oncology

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

Madan L. Arora, MD

Latest:

Dr. Arora on the Evolution of Treatment in Follicular Lymphoma

Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.

Evan J. Lipson, MD, Johns Hopkins Medicine

Latest:

Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

James Ignatz-Hoover, MD, PhD

Latest:

Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

James Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.

Marc Machaalani, MD

Latest:

Dr Machaalani on the Incidence of ERBB2 Amplifications Across Race, Sex, and Cancer Type

Marc Machaalani, MD, discusses an investigation into the distribution of ERBB2 amplifications across sex, race, and varying cancer types.

Maya Khalil, MD

Latest:

Dr Khalil on the Future Investigations of Immunotherapy in NSCLC

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Georges Azzi, MD

Latest:

Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRC

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.